10x Genomics (NASDAQ: TXG) swings to Q2 loss but lifts 2026 revenue guide
Rhea-AI Filing Summary
10x Genomics reported second-quarter 2026 results with revenue of $151.0 million, down from $172.9 million a year earlier. Excluding $1.6 million and $27.3 million of non-recurring patent litigation settlement revenue in 2026 and 2025, respectively, revenue increased 3% over the prior-year quarter. Gross margin improved to 74% from 72%, driven by lower manufacturing costs including $2.6 million of tariff refunds and lower inventory write-downs, partly offset by reduced non-recurring license and royalty revenue.
Operating expenses were $132.1 million, up 39% from $95.0 million, primarily because the current quarter reflected a $3.4 million gain on settlement versus $40.7 million a year ago; excluding settlement impacts, operating expenses were approximately flat year over year. The company recorded an operating loss of $19.6 million and a net loss of $17.9 million, compared with operating income of $30.1 million and net income of $34.5 million in the prior-year period. Cash, cash equivalents and marketable securities totaled $552.0 million as of June 30, 2026. 10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, representing 2% to 5% growth over 2025 excluding non-recurring settlement revenue, and highlighted the acquisition of Proteintech Genomics and new cancer diagnostics collaborations.
Positive
- Raises 2026 revenue guidance to $610–$630 million, implying 2%–5% growth over 2025 when excluding non-recurring settlement revenue.
Negative
- Quarterly revenue fell to $151.0 million from $172.9 million, driven by a sharp decline in non-recurring license and royalty revenue from prior patent litigation settlements.
- Results swung to a net loss of $17.9 million from net income of $34.5 million in the prior-year quarter, as settlement-related gains declined and operating income turned negative.
Filing Explained
The June 30 balance sheet lists contingent consideration of
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 revenue: $151.0 million
Underlying revenue growth: 3%
Gross margin: 74%
+4 more
7 metrics
Q2 2026 revenue
$151.0 million
For the quarter ended June 30, 2026; compared with $172.9 million in Q2 2025
Underlying revenue growth
3%
Increase over Q2 2025 revenue when excluding non-recurring settlement revenue in both periods
Gross margin
74%
Second quarter 2026 gross margin; up from 72% in the corresponding prior year period
Operating expenses
$132.1 million
Q2 2026 operating expenses; a 39% increase from $95.0 million in Q2 2025 driven by lower settlement gains
Net income (loss) Q2 2026
($17.9 million)
Net loss for the second quarter of 2026 versus net income of $34.5 million a year earlier
Cash and investments
$552.0 million
Cash, cash equivalents and marketable securities as of June 30, 2026
2026 revenue guidance
$610 million to $630 million
Full-year 2026 revenue outlook, raised from a prior range of $600 million to $625 million
Key Terms
patent litigation settlement, license and royalty revenue, stock-based compensation expense, contingent consideration, +1 more
5 terms
patent litigation settlement regulatory
"Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million."
license and royalty revenue financial
"License and royalty revenue was 1,942 for Q2 2026 and 27,751 for Q2 2025."
stock-based compensation expense financial
"Includes stock-based compensation expense as follows for cost of revenue, R&D, and SG&A."
Stock-based compensation expense is the value that a company records when it gives employees or executives shares or options to buy shares as part of their pay. It matters because it shows the true cost of paying employees this way, which can affect the company's profits and how investors see its financial health.
contingent consideration financial
"Contingent consideration, current, was 7,069 and noncurrent was 2,991 at June 30, 2026."
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
operating lease right-of-use assets financial
"Operating lease right-of-use assets totaled 56,685 at June 30, 2026."
An operating lease right-of-use (ROU) asset is an accounting entry that shows the value of a leased item you have the legal right to use—like a building, vehicle, or equipment—recorded on a company’s balance sheet along with the corresponding lease obligation. Investors care because it adds to reported assets and liabilities, changing measures like leverage and return on assets much like bringing a long-term rental onto the company’s financial snapshot, which can affect credit terms and valuation.
Earnings Snapshot
Revenue: $151.0 million · Guidance included
Quarter ended June 30, 2026
Revenue
$151.0 million
Down from $172.9 million in the corresponding period of 2025
Net income (loss)
($17.9 million)
Compared to net income of $34.5 million in the prior-year quarter
Gross margin
74%
Up from 72% in the corresponding prior year period
Full-year 2026 revenue guidance
$610 million to $630 million
Raised from the previous range of $600 million to $625 million
Guidance
Revenue expected to be between $610 million and $630 million for full-year 2026, representing 2% to 5% growth over full year 2025 excluding non-recurring license and royalty revenue related to patent litigation settlements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were 10x Genomics (TXG) revenues in Q2 2026?
10x Genomics reported Q2 2026 revenue of $151.0 million, compared with $172.9 million in Q2 2025. Excluding non-recurring patent litigation settlement revenue in both periods, revenue increased 3% year over year, reflecting underlying growth in the core business.
Did 10x Genomics (TXG) report a profit or loss for Q2 2026?
10x Genomics posted a net loss of $17.9 million for Q2 2026, versus net income of $34.5 million a year earlier. The company also recorded an operating loss of $19.6 million, compared with operating income of $30.1 million in the prior-year quarter.
What guidance did 10x Genomics (TXG) provide for full-year 2026 revenue?
10x Genomics raised full-year 2026 revenue guidance to $610 million–$630 million, up from a prior range of $600 million–$625 million. The company said this represents 2%–5% growth over 2025 when excluding non-recurring settlement-related revenue.
How strong is 10x Genomics (TXG) cash position as of June 30, 2026?
As of June 30, 2026, 10x Genomics held $552.0 million in cash, cash equivalents and marketable securities. Total assets were $1,030.1 million and stockholders’ equity was $825.5 million, indicating a substantial capital base to support operations and growth initiatives.
What strategic initiatives did 10x Genomics (TXG) highlight for Q2 2026?
10x Genomics completed the acquisition of Proteintech Genomics, enhancing its multiomics and protein detection capabilities, and announced multi-year collaborations with Cleveland Clinic and Lausanne University Hospital to advance diagnostic applications of its single cell and spatial technologies in cancer care.
How did 10x Genomics (TXG) geographic revenue mix look in Q2 2026?
In Q2 2026, Americas revenue was $85.0 million, including $82.1 million from the United States. EMEA contributed $40.0 million, while Asia-Pacific totaled $26.0 million, with $15.0 million from China and $11.1 million from the rest of Asia-Pacific.
What was 10x Genomics (TXG) gross margin and cost profile in Q2 2026?
10x Genomics reported a gross margin of 74% in Q2 2026, up from 72% a year earlier. Cost of products and services revenue was $38.5 million, benefiting from lower manufacturing costs, including $2.6 million of tariff refunds, and reduced inventory write-downs.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(925 ) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | Description of Exhibits | ||||||||||
| 99.1 | Press Release dated August 6, 2026. | ||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc. | ||||||||
By: | /s/ Randy Wu | |||||||
Name: | Randy Wu | |||||||
Title: | General Counsel and Secretary | |||||||
| Date: August 6, 2026 | ||||||||
Exhibit 99.1
10x Genomics Reports Second Quarter 2026 Financial Results
PLEASANTON, Calif. August 6, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026.
Recent Updates
•Revenue was $151.0 million for the second quarter of 2026. Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million. Revenue increased 3% over the corresponding period of 2025 when excluding non-recurring settlement revenue in both the current and prior-year periods.
•Acquired Proteintech Genomics, a division within Proteintech Group, strengthening the company's multiomics strategy by adding advanced protein detection capabilities to its single cell and spatial platforms.
•Announced multi-year research collaborations with Cleveland Clinic and Lausanne University Hospital to advance research in diagnostic applications of single cell and spatial technologies for cancer care, furthering the company’s diagnostics strategy.
“The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and the very strong early order flow,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “Combined with the continued momentum across the rest of the business and our strong operating foundation, we are uniquely well-positioned for the opportunities ahead.”
Second Quarter 2026 Financial Results
Revenue was $151.0 million for the second quarter of 2026, as compared to $172.9 million for the corresponding period of 2025. Excluding $1.6 million and $27.3 million of non-recurring revenue related to patent litigation settlements in the second quarter of 2026 and 2025, respectively, revenue increased 3% over the corresponding period of 2025.
Gross margin was 74% for the second quarter of 2026, as compared to 72% for the corresponding prior year period. The increase in gross margin was primarily due to lower manufacturing costs, which included $2.6 million of tariff refunds, as well as lower inventory write-downs, partially offset by a decrease in non-recurring license and royalty revenue.
Operating expenses were $132.1 million for the second quarter of 2026, a 39% increase from $95.0 million for the corresponding prior year period. The increase was primarily due to a lower gain on settlement of $3.4 million recognized in the second quarter of 2026, as compared to a $40.7 million gain on settlement recognized in the second quarter of 2025. Excluding impacts from settlements, operating expenses were approximately flat year-over-year.
Operating loss was $19.6 million for the second quarter of 2026, as compared to operating income of $30.1 million for the corresponding prior year period.
Net loss was $17.9 million for the second quarter of 2026, as compared to net income of $34.5 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $552.0 million as of June 30, 2026.
2026 Financial Guidance
10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 2% to 5% growth over full year 2025.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the
1
conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," “outlook,” "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.’s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics’ expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company’s quarterly report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the U.S. Securities and Exchange Commission (“SEC”), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
2
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Products and services revenue | $ | 149,094 | $ | 145,157 | $ | 298,990 | $ | 282,980 | |||||||||||||||
| License and royalty revenue | 1,942 | 27,751 | 2,889 | 44,811 | |||||||||||||||||||
Revenue (1) | 151,036 | 172,908 | 301,879 | 327,791 | |||||||||||||||||||
Cost of products and services revenue (2) | 38,539 | 47,824 | 83,204 | 97,262 | |||||||||||||||||||
| Gross profit | 112,497 | 125,084 | 218,675 | 230,529 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
Research and development (2) | 56,791 | 61,224 | 113,638 | 125,469 | |||||||||||||||||||
Selling, general and administrative (2) | 78,661 | 74,434 | 145,038 | 164,162 | |||||||||||||||||||
| Gain on settlement | (3,400) | (40,700) | (3,400) | (49,900) | |||||||||||||||||||
| Total operating expenses | 132,052 | 94,958 | 255,276 | 239,731 | |||||||||||||||||||
| Income (loss) from operations | (19,555) | 30,126 | (36,601) | (9,202) | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Interest income | 4,797 | 4,271 | 9,811 | 7,957 | |||||||||||||||||||
| Interest expense | — | (3) | — | (3) | |||||||||||||||||||
| Other income (expense), net | (3,887) | 2,603 | (4,702) | 4,739 | |||||||||||||||||||
| Total other income | 910 | 6,871 | 5,109 | 12,693 | |||||||||||||||||||
| Income (loss) before provision for income taxes | (18,645) | 36,997 | (31,492) | 3,491 | |||||||||||||||||||
| Provision for (benefit from) income taxes | (714) | 2,459 | (91) | 3,311 | |||||||||||||||||||
| Net income (loss) | $ | (17,931) | $ | 34,538 | $ | (31,401) | $ | 180 | |||||||||||||||
| Net income (loss) per share, basic | $ | (0.14) | $ | 0.28 | $ | (0.24) | $0.00 | ||||||||||||||||
| Net income (loss) per share, diluted | $ | (0.14) | $ | 0.28 | $ | (0.24) | $0.00 | ||||||||||||||||
| Weighted-average shares used to compute net income (loss) per share, basic | 129,984,169 | 123,755,409 | 129,050,312 | 123,183,924 | |||||||||||||||||||
| Weighted-average shares used to compute net income (loss) per share, diluted | 129,984,169 | 124,509,720 | 129,050,312 | 124,258,150 | |||||||||||||||||||
__________________________
3
(1) The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company’s Visium and Xenium products:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Instruments | |||||||||||||||||||||||
| Single Cell | $ | 3,087 | $ | 5,727 | $ | 8,310 | $ | 11,640 | |||||||||||||||
| Spatial | 4,574 | 8,770 | $ | 10,613 | 17,672 | ||||||||||||||||||
| Total instruments revenue | 7,661 | 14,497 | 18,923 | 29,312 | |||||||||||||||||||
| Consumables | |||||||||||||||||||||||
| Single Cell | 88,451 | 85,788 | 177,345 | 169,897 | |||||||||||||||||||
| Spatial | 42,301 | 36,397 | 83,208 | 67,644 | |||||||||||||||||||
| Total consumables revenue | 130,752 | 122,185 | 260,553 | 237,541 | |||||||||||||||||||
| Services | 10,681 | 8,475 | 19,514 | 16,127 | |||||||||||||||||||
| Products and services revenue | 149,094 | 145,157 | $ | 298,990 | $ | 282,980 | |||||||||||||||||
| License and royalty revenue | 1,942 | 27,751 | $ | 2,889 | $ | 44,811 | |||||||||||||||||
| Total revenue | $ | 151,036 | $ | 172,908 | $ | 301,879 | $ | 327,791 | |||||||||||||||
(1) The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Americas | |||||||||||||||||||||||
United States* | $ | 82,109 | $ | 103,491 | $ | 158,802 | $ | 190,309 | |||||||||||||||
| Americas (excluding United States) | 2,917 | 2,667 | $ | 6,323 | 6,419 | ||||||||||||||||||
| Total Americas | 85,026 | 106,158 | 165,125 | 196,728 | |||||||||||||||||||
| Europe, Middle East and Africa | 39,972 | 34,734 | 76,824 | 66,629 | |||||||||||||||||||
| Asia-Pacific | |||||||||||||||||||||||
| China | 14,968 | 23,170 | 30,805 | 40,053 | |||||||||||||||||||
| Asia-Pacific (excluding China) | 11,070 | 8,846 | 29,125 | 24,381 | |||||||||||||||||||
| Total Asia-Pacific | 26,038 | 32,016 | 59,930 | 64,434 | |||||||||||||||||||
| Total revenue | $ | 151,036 | $ | 172,908 | $ | 301,879 | $ | 327,791 | |||||||||||||||
* Includes license and royalty revenue.
(2) Includes stock-based compensation expense as follows:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
(in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Cost of revenue | $ | 1,836 | $ | 1,989 | $ | 3,754 | $ | 4,470 | |||||||||||||||
| Research and development | 10,533 | 12,613 | 21,228 | 26,719 | |||||||||||||||||||
| Selling, general and administrative | 13,247 | 12,643 | 23,276 | 27,132 | |||||||||||||||||||
| Total stock-based compensation expense | $ | 25,616 | $ | 27,245 | $ | 48,258 | $ | 58,321 | |||||||||||||||
4
10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
| June 30, 2026 | December 31, 2025 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 502,512 | $ | 473,966 | |||||||
| Marketable securities | 49,521 | 49,443 | |||||||||
| Accounts receivable, net | 47,545 | 47,013 | |||||||||
| Other receivables | 3,084 | 35,480 | |||||||||
| Inventory | 52,616 | 56,341 | |||||||||
| Prepaid expenses and other current assets | 19,393 | 22,208 | |||||||||
| Total current assets | 674,671 | 684,451 | |||||||||
| Property and equipment, net | 215,324 | 226,711 | |||||||||
| Operating lease right-of-use assets | 56,685 | 60,450 | |||||||||
| Goodwill | 6,918 | 4,511 | |||||||||
| Intangible assets, net | 61,160 | 62,329 | |||||||||
| Other noncurrent assets | 15,308 | 2,913 | |||||||||
| Total assets | $ | 1,030,066 | $ | 1,041,365 | |||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 20,694 | $ | 12,733 | |||||||
| Accrued compensation and related benefits | 24,744 | 42,500 | |||||||||
| Accrued expenses and other current liabilities | 30,377 | 39,971 | |||||||||
| Deferred revenue | 23,610 | 23,902 | |||||||||
| Operating lease liabilities | 12,015 | 10,985 | |||||||||
| Contingent consideration, current | 7,069 | 23,363 | |||||||||
| Total current liabilities | 118,509 | 153,454 | |||||||||
| Contingent consideration, noncurrent | 2,991 | 1,237 | |||||||||
| Operating lease liabilities, noncurrent | 66,781 | 73,376 | |||||||||
| Deferred revenue, noncurrent | 9,683 | 10,501 | |||||||||
| Other noncurrent liabilities | 6,556 | 6,471 | |||||||||
| Total liabilities | 204,520 | 245,039 | |||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock | — | — | |||||||||
| Common stock | 2 | 2 | |||||||||
| Additional paid-in capital | 2,367,459 | 2,306,690 | |||||||||
| Accumulated deficit | (1,541,992) | (1,510,591) | |||||||||
| Accumulated other comprehensive income | 77 | 225 | |||||||||
| Total stockholders’ equity | 825,546 | 796,326 | |||||||||
| Total liabilities and stockholders’ equity | $ | 1,030,066 | $ | 1,041,365 | |||||||
5